Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  European Urology

• Publication date

  2006-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.EURURO.2006.05.036PMID 16820261
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Health-Related Quality of Life in a UK-Based Population of Men with Erectile Dysfunction

  2012cited by this paper
• Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.

  2006cited by this paper
• EAU Guidelines on erectile dysfunction: an update.

  2006cited by this paper
• [Efficacy and tolerability of vardenafil within the time window of 6 hours after administration and beyond].

  2005cited by this paper
• Women's sexual function improves when partners are administered vardenafil for erectile dysfunction: a prospective, randomized, double-blind, placebo-controlled trial.

  2005cited by this paper
• Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) study.

  2005cited by this paper
• Efficacy and tolerability of vardenafil within the time window of 6 hours after administration and beyond

  2005cited by this paper
• Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, randomized, placebo-controlled trial of vardenafil.

  2005cited by this paper
• Penetration and maintenance of erection with vardenafil: a time-from-dosing analysis.

  2005cited by this paper
• Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience.

  2005cited by this paper
• Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled study.

  2005cited by this paper
• Phosphodiesterase type 5 inhibitors for erectile dysfunction

  2005cited by this paper
• Erratum: Erectile response with vardenafil in sildenafil nonresponders: A multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial (BJU International (2004) 94 (1301-1309))

  2005cited by this paper
• Chapter 1: The management of erectile dysfunction: an AUA update.

  2005cited by this paper
• Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events

  2004cited by this paper
• Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study.

  2004cited by this paper
• The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men.

  2004cited by this paper
• Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial.

  2004cited by this paper
• Erection quality scale: initial scale development and validation.

  2004cited by this paper
• Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction

  2004cited by this paper
• Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window.

  2004cited by this paper
• Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double‐blind, 12‐week, flexible‐dose, placebo‐controlled erectile dysfunction clinical trial

  2004cited by this paper
• Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.

  2004cited by this paper
• The use of phosphodiesterase type 5 inhibitors for erectile dysfunction.

  2004cited by this paper
• American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update.

  2003cited by this paper
• Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study.

  2003cited by this paper
• Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy.

  2003cited by this paper
• Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial.

  2003cited by this paper
• The effect of erectile dysfunction on the quality of life of men after radical prostatectomy

  2003cited by this paper
• PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS

  2002cited by this paper
• Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked.

  2002cited by this paper
• Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial.

  2002cited by this paper
• Quality of life and erectile dysfunction.

  2002cited by this paper
• The worldwide prevalence and epidemiology of erectile dysfunction

  2000cited by this paper
• Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function.

  2000cited by this paper
• The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences

  1999cited by this paper

• Determination of Vardenafil in Human Plasma by LC/MS/MS and its Clinical Applications

  2022cites this paper
• Safety, Tolerability, and Pharmacokinetics of RT234 (Vardenafil Inhalation Powder): A First-in-Human, Ascending Single- and Multiple-Dose Study in Healthy Subjects

  2020cites this paper
• Reflexionen über 50 Jahre Sexualmedizin in der Urologie mit Fokus auf männliche Sexualstörungen

  2019cites this paper
• Erectile Dysfunction: AUA Guideline

  2018cites this paper
• The Textbook of Clinical Sexual Medicine

  2017cites this paper
• Sex and Pharmacological Sexual Enhancement

  2017cites this paper
• Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan

  2016cites this paper
• Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).

  2016cites this paper
• A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction

  2015cites this paper
• PDE5 Inhibitors for the Treatment of Erectile Dysfunction in Patients with Hypertension

  2015cites this paper
• An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy

  2014cites this paper
• Udenafil for the treatment of erectile dysfunction

  2014cites this paper
• SOP conservative (medical and mechanical) treatment of erectile dysfunction.

  2013cites this paper
• Between the Local and the Global: Chronicles for Understanding the Field of Sexology in Mexico

  2013cites this paper
• [Erectile dysfunction: conservative treatment and new approaches].

  2012cites this paper
• Chronic PDE-5 inhibition in patients with erectile dysfunction – a treatment approach using tadalafil once-daily

  2012cites this paper
• Vardenafil for the treatment of erectile dysfunction

  2012cites this paper
• A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

  2012cites this paper
• Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction.

  2011cites this paper
• Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians.

  2009cites this paper
• Chronische PDE-5-Hemmung bei erektiler Dysfunktion

  2009cites this paper
• Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence

  2009cites this paper
• Phosphodiesterase type 5 inhibitors: unmet needs.

  2009cites this paper
• Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis

  2009cites this paper
• Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence

  2009cites this paper
• Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction

  2009cites this paper
• Vardenafi l in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

  2008cites this paper
• Sildenafil citrate efficacy 8 h postdose in men with mild to moderate erectile dysfunction

  2008cites this paper
• Erectile dysfunction.

  2008cites this paper
• Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

  2008cites this paper
• Product-related research: how research can contribute to successful life-cycle management.

  2008cites this paper
• A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

  2008cites this paper
• Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.

  2008cites this paper
• The Case for Postoperative PDE-5 Inhibitor Drug Treatment after Radical Prostatectomy

  2008cites this paper
• Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

  2008cites this paper
• Editorial comment on: comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.

  2008cites this paper
• Wirksamkeit und Sicherheit der Therapie der erektilen Dysfunktion mit Vardenafil unter Routinebedingungen Ergebnisse von 9946 Patienten aus Deutschland

  2007cites this paper
• Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?

  2007cites this paper
• Phosphodiesterase type 5 inhibitors: the day after.

  2007cites this paper
• Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study

  2007cites this paper
• Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction

  2007cites this paper
• Vardenafil duration of action.

  2006cites this paper
• Vardenafil duration of action.

  2006cites this paper
• Clinical Interventions in Aging Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Vardenafil for the Treatment of Erectile Dysfunction: an Overview of the Clinical Evidence

  year unknowncites this paper